Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and ELIAS JOSEPH JABBOUR.
Connection Strength
100.734
-
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol. 2024 Nov 21.
Score: 0.998
-
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Oct; 38(10):2291.
Score: 0.989
-
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024 Nov; 99(11):2191-2212.
Score: 0.977
-
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol. 2024 Jul 19; JCO2400272.
Score: 0.975
-
Ponatinib-review of historical development, current status, and future research. Am J Hematol. 2024 08; 99(8):1576-1585.
Score: 0.962
-
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
Score: 0.956
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 04; 99(4):586-595.
Score: 0.945
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 02 01; 143(5):417-421.
Score: 0.944
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 03; 38(3):475-481.
Score: 0.944
-
Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol. 2023 Oct; 10(10):e860-e864.
Score: 0.916
-
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
Score: 0.898
-
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44.
Score: 0.896
-
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023 03 16; 16(1):22.
Score: 0.888
-
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665.
Score: 0.881
-
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501.
Score: 0.876
-
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan; 10(1):e24-e34.
Score: 0.868
-
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885.
Score: 0.864
-
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022 Nov; 9(11):e854-e861.
Score: 0.860
-
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA Oncol. 2022 09 01; 8(9):1340-1348.
Score: 0.856
-
Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 11; 97(11):1413-1418.
Score: 0.855
-
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 09; 97(9):1236-1256.
Score: 0.847
-
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 09; 97(9):1135-1141.
Score: 0.845
-
The cure of leukemia through the optimist's prism. Cancer. 2022 01 15; 128(2):240-259.
Score: 0.804
-
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. 2021 10 01; 96(10):E379-E383.
Score: 0.790
-
A new era in the treatment of acute lymphoblastic leukemia. Blood. 2021 03 25; 137(12):1563-1564.
Score: 0.775
-
The clinical development of antibody-drug conjugates - lessons from leukaemia. Nat Rev Clin Oncol. 2021 07; 18(7):418-433.
Score: 0.774
-
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.
Score: 0.774
-
The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2021 01; 21(1):63-65.
Score: 0.753
-
Management of Older Patients with Acute Lymphocytic Leukemia - Novel Treatment Strategies. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S30-S31.
Score: 0.745
-
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
Score: 0.736
-
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020 06; 95(6):691-709.
Score: 0.725
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586.
Score: 0.677
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
Score: 0.660
-
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
Score: 0.653
-
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018 10 01; 4(10):1413-1420.
Score: 0.652
-
Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:574-578.
Score: 0.636
-
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 03; 93(3):442-459.
Score: 0.626
-
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 04; 18(4):257-265.
Score: 0.625
-
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
Score: 0.623
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.621
-
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.
Score: 0.600
-
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
Score: 0.600
-
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv. 2016 Dec 27; 1(3):260-264.
Score: 0.577
-
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
Score: 0.565
-
Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet. 2016 Jun 11; 387(10036):2360-1.
Score: 0.550
-
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016 Feb; 91(2):252-65.
Score: 0.542
-
Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015 Jun 25; 125(26):4010-6.
Score: 0.517
-
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015 Aug 01; 121(15):2517-28.
Score: 0.513
-
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6.
Score: 0.504
-
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4.
Score: 0.487
-
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014 May; 89(5):547-56.
Score: 0.480
-
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52.
Score: 0.467
-
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.
Score: 0.465
-
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83.
Score: 0.461
-
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29.
Score: 0.455
-
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8.
Score: 0.437
-
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
Score: 0.433
-
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol. 2012 Nov; 87(11):1037-45.
Score: 0.433
-
Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):223-9.
Score: 0.420
-
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
Score: 0.417
-
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10; 119(19):4524-6.
Score: 0.415
-
Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer. 2012 Mar 01; 118(5):1181-91.
Score: 0.404
-
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011 May 01; 117(9):1800-11.
Score: 0.379
-
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer. 2011 Mar 01; 117(5):897-906.
Score: 0.375
-
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4.
Score: 0.371
-
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid. 2010 Jun 15; 4:207-13.
Score: 0.367
-
Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009 Sep; 22(3):395-407.
Score: 0.348
-
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009 May; 14(5):489-96.
Score: 0.338
-
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 02; 84(2):161-9.
Score: 0.334
-
Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009 Jan; 4(1):3-10.
Score: 0.334
-
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36.
Score: 0.320
-
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun; 112(11):2341-51.
Score: 0.319
-
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008 May 15; 112(10):2112-8.
Score: 0.318
-
Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008 Jan; 8(1):99-110.
Score: 0.310
-
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J. 2007 Nov-Dec; 13(6):357-65.
Score: 0.306
-
Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007 Jun 01; 109(11):2171-81.
Score: 0.297
-
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 2007 May; 16(5):679-87.
Score: 0.296
-
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8.
Score: 0.296
-
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 2:S51-7.
Score: 0.292
-
Introduction: chronic myelogenous leukemia (CML). Semin Hematol. 2007 Jan; 44(1 Suppl 1):S1-3.
Score: 0.289
-
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31.
Score: 0.289
-
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2006 Nov; 18(6):578-83.
Score: 0.286
-
Adult acute myeloid leukemia. Mayo Clin Proc. 2006 Feb; 81(2):247-60.
Score: 0.271
-
Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005 Nov; 80(11):1517-27.
Score: 0.266
-
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024 Nov 19; 14(1):203.
Score: 0.249
-
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec; 38(12):2717-2721.
Score: 0.247
-
Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024 09 19; 14(1):163.
Score: 0.247
-
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol. 2024 Nov; 99(11):2229-2232.
Score: 0.246
-
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024 08 07; 14(1):129.
Score: 0.245
-
Optimal frontline therapy of chronic myeloid leukemia today, and related musings. Am J Hematol. 2024 Oct; 99(10):1855-1861.
Score: 0.244
-
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. Cancer. 2024 Nov 01; 130(21):3631-3646.
Score: 0.244
-
Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma. 2024 Oct; 65(10):1405-1417.
Score: 0.242
-
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024 06 04; 331(21):1814-1823.
Score: 0.242
-
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024 Oct 01; 130(19):3344-3352.
Score: 0.241
-
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia? Expert Rev Hematol. 2024 Jun; 17(6):189-191.
Score: 0.241
-
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol. 2024 05 11; 17(1):32.
Score: 0.241
-
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024 07; 99(7):1423-1426.
Score: 0.239
-
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. Am J Hematol. 2024 06; 99(6):1175-1176.
Score: 0.239
-
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia. 2024 May; 38(5):947-950.
Score: 0.238
-
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk. 2024 Jul; 24(7):484-487.
Score: 0.237
-
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 02 27; 8(4):909-915.
Score: 0.237
-
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 05; 99(5):836-843.
Score: 0.237
-
SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jul; 24(7):427-432.
Score: 0.237
-
Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):375-381.
Score: 0.236
-
A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):285-297.
Score: 0.235
-
SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):333-339.
Score: 0.235
-
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e168-e173.
Score: 0.235
-
SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):271-276.
Score: 0.234
-
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023 12 01; 129(23):3805-3814.
Score: 0.230
-
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
Score: 0.229
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.
Score: 0.228
-
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73.
Score: 0.227
-
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748.
Score: 0.225
-
Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203.
Score: 0.225
-
Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023 04 24; 13(1):58.
Score: 0.224
-
The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2023 Feb; 21(2):68-75.
Score: 0.220
-
SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clin Lymphoma Myeloma Leuk. 2023 04; 23(4):238-243.
Score: 0.220
-
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029.
Score: 0.220
-
Chronic myeloid leukemia without major molecular response after 2?years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023 04; 98(4):639-644.
Score: 0.220
-
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 11; 97(11):1427-1434.
Score: 0.215
-
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 11; 97(11):1419-1426.
Score: 0.214
-
Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022 09; 97(9):E350-E352.
Score: 0.212
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
Score: 0.212
-
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857.
Score: 0.211
-
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 01; 98(1):E11-E14.
Score: 0.211
-
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
Score: 0.210
-
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035.
Score: 0.210
-
Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 May; 36(5):1448.
Score: 0.209
-
Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876.
Score: 0.208
-
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864.
Score: 0.208
-
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022 06 01; 97(6):E201-E204.
Score: 0.207
-
Management of acute lymphoblastic leukemia in older adults. Clin Adv Hematol Oncol. 2022 Mar; 20(3):161-168.
Score: 0.207
-
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260.
Score: 0.206
-
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12.
Score: 0.205
-
Prediction for sustained deep molecular response for treatment-free remission. Leuk Lymphoma. 2022 01; 63(1):5-6.
Score: 0.204
-
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419.
Score: 0.204
-
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 01 01; 97(1):68-78.
Score: 0.202
-
Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 10 26; 5(20):3913-3918.
Score: 0.202
-
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377.
Score: 0.201
-
SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022 02; 22(2):61-66.
Score: 0.199
-
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021 11; 35(11):3044-3058.
Score: 0.197
-
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
Score: 0.197
-
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):1000-1007.
Score: 0.196
-
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
Score: 0.196
-
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
Score: 0.196
-
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647.
Score: 0.194
-
De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021 06 15; 127(12):2049-2061.
Score: 0.194
-
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
Score: 0.194
-
Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021 06 01; 96(6):650-658.
Score: 0.194
-
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598.
Score: 0.193
-
Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 02 22; 11(2):41.
Score: 0.193
-
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
Score: 0.192
-
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol. 2021; 144(3):285-292.
Score: 0.189
-
Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020 12; 33(4):101226.
Score: 0.189
-
Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2020 12; 33(4):101225.
Score: 0.189
-
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
Score: 0.187
-
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 09; 95(9):E245-E247.
Score: 0.185
-
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e871-e882.
Score: 0.183
-
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61.
Score: 0.183
-
Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145.
Score: 0.182
-
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015.
Score: 0.182
-
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
Score: 0.182
-
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.
Score: 0.179
-
Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696.
Score: 0.177
-
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
Score: 0.177
-
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
Score: 0.176
-
Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol. 2020 01; 188(2):207-223.
Score: 0.175
-
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
Score: 0.175
-
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019 Dec 01; 125(23):4181-4192.
Score: 0.173
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
Score: 0.173
-
Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? Cancer. 2019 11 01; 125(21):3891-3892.
Score: 0.172
-
SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):471-479.
Score: 0.172
-
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 12; 60(13):3172-3180.
Score: 0.170
-
Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019 11; 60(11):2606-2621.
Score: 0.170
-
Recent Advances in Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2019 04; 14(2):106-118.
Score: 0.169
-
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
Score: 0.169
-
Treatment of relapsed/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 Mar; 17(3):166-175.
Score: 0.168
-
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673.
Score: 0.167
-
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416.
Score: 0.166
-
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 02; 94(2):257-265.
Score: 0.165
-
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Ther Adv Hematol. 2018; 9(12):347-356.
Score: 0.165
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.164
-
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
Score: 0.163
-
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
Score: 0.162
-
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
Score: 0.161
-
SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 07; 18(7):439-446.
Score: 0.159
-
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
Score: 0.158
-
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
Score: 0.158
-
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018 05 15; 124(10):2151-2160.
Score: 0.157
-
Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar; 16(3):216-223.
Score: 0.157
-
L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):e191-e195.
Score: 0.156
-
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695.
Score: 0.156
-
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
Score: 0.156
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.155
-
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol. 2018 Feb; 93(2):286-295.
Score: 0.153
-
Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer. 2017 12 15; 123(24):4935-4936.
Score: 0.153
-
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326.
Score: 0.151
-
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.
Score: 0.151
-
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin. Future Oncol. 2017 Oct; 13(25):2233-2242.
Score: 0.150
-
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
Score: 0.150
-
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597.
Score: 0.150
-
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
Score: 0.150
-
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398.
Score: 0.150
-
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
Score: 0.149
-
Blinatumomab for Acute Lymphoblastic Leukemia. N Engl J Med. 2017 06 08; 376(23):e49.
Score: 0.149
-
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017 Jul; 92(7):660-667.
Score: 0.149
-
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
Score: 0.147
-
Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol. 2017 Apr; 15(4):266-274.
Score: 0.147
-
Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403.
Score: 0.147
-
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
Score: 0.146
-
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6.
Score: 0.146
-
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243.
Score: 0.145
-
Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016 Nov; 91(11):1645-1666.
Score: 0.143
-
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
Score: 0.142
-
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
Score: 0.142
-
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
Score: 0.142
-
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
Score: 0.141
-
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656.
Score: 0.140
-
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491.
Score: 0.140
-
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
Score: 0.139
-
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9.
Score: 0.137
-
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb; 91(2):227-32.
Score: 0.136
-
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):139-45.
Score: 0.134
-
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
Score: 0.133
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
Score: 0.132
-
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
Score: 0.132
-
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110.
Score: 0.131
-
Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Drugs Today (Barc). 2015 Apr; 51(4):231-41.
Score: 0.128
-
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82.
Score: 0.128
-
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):323-34.
Score: 0.128
-
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34.
Score: 0.127
-
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82.
Score: 0.125
-
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61.
Score: 0.124
-
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21.
Score: 0.124
-
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.
Score: 0.122
-
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
Score: 0.122
-
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87.
Score: 0.121
-
Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol. 2014 Apr; 5(2):29-34.
Score: 0.119
-
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
Score: 0.119
-
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35.
Score: 0.119
-
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5.
Score: 0.118
-
Clofarabine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2014 Feb; 23(2):255-63.
Score: 0.118
-
Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs. 2014 Mar; 19(1):37-50.
Score: 0.117
-
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500.
Score: 0.117
-
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014 Jul; 55(7):1451-62.
Score: 0.116
-
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94.
Score: 0.114
-
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.
Score: 0.114
-
Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leuk Lymphoma. 2013 Dec; 54(12):2592-600.
Score: 0.113
-
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6.
Score: 0.113
-
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):559-67.
Score: 0.113
-
Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83.
Score: 0.113
-
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
Score: 0.113
-
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
Score: 0.112
-
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013 Jul 15; 119(14):2611-9.
Score: 0.112
-
Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013 Apr; 4(2):103-17.
Score: 0.111
-
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.
Score: 0.110
-
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6.
Score: 0.110
-
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
Score: 0.108
-
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
Score: 0.108
-
The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013 Apr; 54(4):688-98.
Score: 0.108
-
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies. Oncology (Williston Park). 2012 Sep; 26(9):851-9.
Score: 0.107
-
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200.
Score: 0.105
-
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10.
Score: 0.105
-
Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38.
Score: 0.105
-
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012 Jul; 87(7):687-91.
Score: 0.104
-
Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012 Apr; 13(6):815-28.
Score: 0.104
-
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22.
Score: 0.103
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
Score: 0.103
-
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7.
Score: 0.103
-
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7.
Score: 0.102
-
Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v.
Score: 0.101
-
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10; 29(32):4260-5.
Score: 0.101
-
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):682-92.
Score: 0.100
-
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6.
Score: 0.099
-
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759.
Score: 0.099
-
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.
Score: 0.099
-
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8.
Score: 0.099
-
Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2011 Jun; 4(3):253-60.
Score: 0.098
-
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902.
Score: 0.098
-
Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol. 2011 May; 7(5):661-72.
Score: 0.097
-
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10.
Score: 0.097
-
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93.
Score: 0.097
-
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41.
Score: 0.097
-
Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica. 2011 Mar; 96(3):347-9.
Score: 0.096
-
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.
Score: 0.096
-
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1674-83.
Score: 0.096
-
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011 Feb; 52 Suppl 1:81-91.
Score: 0.096
-
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7.
Score: 0.095
-
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother. 2010 Dec; 11(18):3065-72.
Score: 0.094
-
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7.
Score: 0.094
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
Score: 0.094
-
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010 Oct; 47(4):344-53.
Score: 0.094
-
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010 Oct 01; 116(19):4580-9.
Score: 0.094
-
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74.
Score: 0.093
-
Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94.
Score: 0.093
-
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9.
Score: 0.093
-
Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol. 2010 Jul; 47(3):274-80.
Score: 0.092
-
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10 Suppl 1:S6-13.
Score: 0.092
-
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010 May 15; 116(10):2290-300.
Score: 0.091
-
Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs. 2010 Mar; 15(1):1-11.
Score: 0.090
-
Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb; 3(1):15-22.
Score: 0.089
-
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20; 28(3):398-404.
Score: 0.089
-
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010 Jan 20; 28(3):392-7.
Score: 0.089
-
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010 Jan; 24(1):6-12.
Score: 0.087
-
Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2009 Jul; 4(3):148-56.
Score: 0.086
-
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43.
Score: 0.086
-
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009 Aug 01; 27(22):3659-63.
Score: 0.085
-
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
Score: 0.085
-
Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther. 2009 Feb 06; 2:233-43.
Score: 0.084
-
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9.
Score: 0.083
-
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60.
Score: 0.083
-
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42.
Score: 0.081
-
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008 Sep 01; 113(5):985-94.
Score: 0.081
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5.
Score: 0.079
-
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S75-81.
Score: 0.078
-
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008 Mar 01; 112(5):1089-95.
Score: 0.078
-
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8.
Score: 0.077
-
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302.
Score: 0.076
-
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4.
Score: 0.075
-
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5.
Score: 0.075
-
Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar; 16(3):381-92.
Score: 0.073
-
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73.
Score: 0.072
-
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8.
Score: 0.072
-
Dasatinib. Nat Rev Drug Discov. 2006 Sep; 5(9):717-8.
Score: 0.071
-
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73.
Score: 0.070
-
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60.
Score: 0.070
-
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3.
Score: 0.069
-
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8.
Score: 0.068
-
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24.
Score: 0.067
-
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2.
Score: 0.066
-
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
Score: 0.065
-
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol. 2024 Nov 15; 17(1):112.
Score: 0.062
-
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024 Nov 01; 109(11):3543-3556.
Score: 0.062
-
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95.
Score: 0.062
-
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res. 2024 Dec; 147:107602.
Score: 0.062
-
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther. 2024 Sep 26.
Score: 0.062
-
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. 2024 Nov; 11(11):e839-e849.
Score: 0.062
-
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084.
Score: 0.061
-
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
Score: 0.061
-
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract. 2024 Jul 16; OP2400027.
Score: 0.061
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 07 04; 144(1):61-73.
Score: 0.061
-
Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):783-788.
Score: 0.061
-
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 06 25; 8(12):3226-3236.
Score: 0.061
-
Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk. 2024 Oct; 24(10):e376-e384.
Score: 0.061
-
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024 Oct 01; 130(19):3333-3343.
Score: 0.060
-
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid. 2024 Jun; 3(6):EVIDoa2300362.
Score: 0.060
-
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. Int J Hematol. 2024 Aug; 120(2):203-211.
Score: 0.060
-
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res. 2024 Jul; 142:107518.
Score: 0.060
-
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 Sep; 24(9):629-633.
Score: 0.060
-
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298.
Score: 0.060
-
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res. 2024 Apr 01; 30(7):1319-1326.
Score: 0.060
-
SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Sep; 24(9):565-572.
Score: 0.059
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
Score: 0.059
-
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 May; 38(5):1178-1181.
Score: 0.059
-
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024 02 27; 8(4):927-935.
Score: 0.059
-
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024 04; 99(4):792-796.
Score: 0.059
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
Score: 0.059
-
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 May 01; 42(13):1499-1508.
Score: 0.059
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 01 01; 109(1):293-297.
Score: 0.059
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv. 2023 Dec 09.
Score: 0.058
-
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
Score: 0.058
-
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148.
Score: 0.058
-
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592.
Score: 0.057
-
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378.
Score: 0.057
-
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. 2023 10; 98(10):E281-E284.
Score: 0.057
-
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581.
Score: 0.057
-
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
Score: 0.057
-
A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293.
Score: 0.057
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
Score: 0.057
-
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393.
Score: 0.057
-
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol. 2023 05; 7:e2200707.
Score: 0.056
-
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942.
Score: 0.056
-
Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 06; 98(6):E142-E144.
Score: 0.056
-
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 06 15; 129(12):1856-1865.
Score: 0.055
-
Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer. 2023 06 15; 129(12):1866-1872.
Score: 0.055
-
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
Score: 0.055
-
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568.
Score: 0.054
-
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589.
Score: 0.054
-
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 11 17; 140(20):2101-2112.
Score: 0.054
-
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023 01; 37(1):5-17.
Score: 0.054
-
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022 10 28; 12(10):144.
Score: 0.054
-
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 12; 97(12):1599-1606.
Score: 0.054
-
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 12; 97(12):1560-1567.
Score: 0.054
-
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 11; 97(11):1443-1452.
Score: 0.054
-
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 11; 97(11):E408-E411.
Score: 0.054
-
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022 Oct; 9(10):e756-e765.
Score: 0.053
-
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034.
Score: 0.053
-
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
Score: 0.053
-
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77.
Score: 0.052
-
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360.
Score: 0.052
-
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894.
Score: 0.052
-
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):e836-e843.
Score: 0.052
-
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma. 2022 07; 63(7):1714-1717.
Score: 0.052
-
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919.
Score: 0.052
-
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.
Score: 0.052
-
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337.
Score: 0.051
-
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2021 Dec 29; 14(1).
Score: 0.051
-
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
Score: 0.050
-
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 09 29; 11(9):162.
Score: 0.050
-
Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428.
Score: 0.050
-
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410.
Score: 0.050
-
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2021 11 15; 127(22):4213-4220.
Score: 0.050
-
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.
Score: 0.050
-
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
Score: 0.050
-
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
Score: 0.050
-
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
Score: 0.049
-
Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94.
Score: 0.049
-
Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021 09; 35(9):2482-2495.
Score: 0.049
-
Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Curr Oncol Rep. 2021 06 14; 23(8):95.
Score: 0.049
-
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
Score: 0.049
-
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.
Score: 0.049
-
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823.
Score: 0.049
-
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. 2021 08 01; 96(8):E275-E279.
Score: 0.049
-
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
Score: 0.049
-
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183.
Score: 0.049
-
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
Score: 0.049
-
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
Score: 0.049
-
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.
Score: 0.049
-
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021 07 01; 96(7):E229-E232.
Score: 0.049
-
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021; 11:639387.
Score: 0.048
-
Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
Score: 0.048
-
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 03 17; 11(3):60.
Score: 0.048
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.048
-
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898.
Score: 0.048
-
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34.
Score: 0.048
-
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25.
Score: 0.048
-
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
Score: 0.048
-
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
Score: 0.048
-
GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. Am J Hematol. 2021 03 01; 96(3):E71-E74.
Score: 0.048
-
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020 12 22; 4(24):6117-6126.
Score: 0.048
-
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917.
Score: 0.047
-
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
Score: 0.047
-
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.
Score: 0.047
-
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
Score: 0.047
-
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996.
Score: 0.047
-
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020 11 10; 4(21):5336-5342.
Score: 0.047
-
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390.
Score: 0.047
-
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.
Score: 0.047
-
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
Score: 0.047
-
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
Score: 0.047
-
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329.
Score: 0.047
-
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
Score: 0.047
-
Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576.
Score: 0.047
-
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.
Score: 0.046
-
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
Score: 0.046
-
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.
Score: 0.046
-
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127.
Score: 0.046
-
The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134.
Score: 0.046
-
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820.
Score: 0.046
-
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
Score: 0.046
-
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 06 05; 13(1):70.
Score: 0.046
-
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.
Score: 0.045
-
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573.
Score: 0.045
-
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320.
Score: 0.045
-
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma. 2020 08; 61(8):1943-1953.
Score: 0.045
-
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020 06; 105(6):1507-1516.
Score: 0.045
-
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e597-e605.
Score: 0.045
-
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
Score: 0.045
-
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
Score: 0.045
-
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
Score: 0.045
-
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495.
Score: 0.045
-
Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
Score: 0.045
-
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer. 2020 03 15; 126(6):1152-1160.
Score: 0.044
-
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020 02 15; 126(4):765-774.
Score: 0.044
-
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395.
Score: 0.044
-
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
Score: 0.044
-
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218.
Score: 0.044
-
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565.
Score: 0.044
-
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766.
Score: 0.043
-
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019 12; 60(13):3292-3295.
Score: 0.043
-
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 09 15; 125(18):3219-3224.
Score: 0.043
-
Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
Score: 0.043
-
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020 03; 105(3):697-707.
Score: 0.043
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
Score: 0.043
-
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol. 2019; 10:2040620719849496.
Score: 0.043
-
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
Score: 0.042
-
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.
Score: 0.042
-
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933.
Score: 0.042
-
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019 06; 94(6):E158-E160.
Score: 0.042
-
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 07 01; 125(13):2233-2241.
Score: 0.042
-
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552.
Score: 0.042
-
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
Score: 0.042
-
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
Score: 0.042
-
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1.
Score: 0.041
-
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):33-39.
Score: 0.041
-
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1.
Score: 0.041
-
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
Score: 0.041
-
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2019 04 01; 125(7):1091-1100.
Score: 0.041
-
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37(1):96-102.
Score: 0.041
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.041
-
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.
Score: 0.041
-
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 04; 104(4):749-755.
Score: 0.041
-
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.
Score: 0.041
-
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer. 2018 10 01; 124(19):3849-3855.
Score: 0.041
-
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 10; 93(10):1245-1253.
Score: 0.041
-
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369.
Score: 0.041
-
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
Score: 0.041
-
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
Score: 0.041
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
Score: 0.041
-
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.
Score: 0.041
-
First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2018; 2.
Score: 0.040
-
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018 08 14; 2(15):1807-1816.
Score: 0.040
-
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670.
Score: 0.040
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
Score: 0.040
-
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
Score: 0.040
-
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018 11; 32(11):2512-2518.
Score: 0.040
-
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
Score: 0.039
-
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2018 04; 13(2):91-99.
Score: 0.039
-
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146.
Score: 0.039
-
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 09; 59(9):2238-2241.
Score: 0.039
-
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
Score: 0.039
-
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
Score: 0.039
-
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
Score: 0.039
-
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334.
Score: 0.039
-
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
Score: 0.038
-
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90.
Score: 0.038
-
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322.
Score: 0.038
-
Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302.
Score: 0.038
-
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018 01; 32(1):241-244.
Score: 0.038
-
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017 12; 102(12):e514-e517.
Score: 0.038
-
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):1012-1015.
Score: 0.038
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
Score: 0.038
-
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091.
Score: 0.038
-
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
Score: 0.038
-
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717.
Score: 0.038
-
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
Score: 0.038
-
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.
Score: 0.037
-
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559.
Score: 0.037
-
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017 09; 30(3):193-200.
Score: 0.037
-
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444.
Score: 0.037
-
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
Score: 0.037
-
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657.
Score: 0.037
-
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060.
Score: 0.037
-
Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017 Jun; 92(6):520-528.
Score: 0.037
-
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
Score: 0.037
-
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587.
Score: 0.037
-
Dorsal column myelopathy after intrathecal chemotherapy for leukemia. Am J Hematol. 2017 Feb; 92(2):155-160.
Score: 0.036
-
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285.
Score: 0.036
-
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017 May 15; 123(6):994-1002.
Score: 0.036
-
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
Score: 0.036
-
Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017 Feb; 110:20-34.
Score: 0.036
-
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
Score: 0.036
-
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581.
Score: 0.036
-
Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol. 2017 Jan; 92(1):E3-E4.
Score: 0.036
-
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
Score: 0.036
-
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
Score: 0.036
-
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016 12; 91(12):1221-1226.
Score: 0.035
-
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343.
Score: 0.035
-
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 11; 16(11):616-624.
Score: 0.035
-
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5.
Score: 0.035
-
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7.
Score: 0.035
-
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7.
Score: 0.035
-
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
Score: 0.034
-
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 06; 101(6):e224-7.
Score: 0.034
-
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.
Score: 0.034
-
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9.
Score: 0.034
-
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. 2016 Apr; 173(1):114-26.
Score: 0.034
-
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 07; 30(7):1606-9.
Score: 0.034
-
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy. 2016 Feb; 8(2):135-43.
Score: 0.034
-
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9.
Score: 0.034
-
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.
Score: 0.034
-
Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016 Jan; 18(1):4.
Score: 0.034
-
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb; 41:43-7.
Score: 0.034
-
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):152-62.
Score: 0.034
-
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2.
Score: 0.033
-
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74.
Score: 0.033
-
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48.
Score: 0.033
-
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016 Mar; 30(3):649-57.
Score: 0.033
-
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73.
Score: 0.033
-
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica. 2015 Dec; 100(12):e494-5.
Score: 0.033
-
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015 Sep; 2(9):e376-83.
Score: 0.033
-
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016 Apr; 30(4):980-4.
Score: 0.033
-
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333.
Score: 0.033
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
Score: 0.033
-
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904.
Score: 0.033
-
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.
Score: 0.033
-
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63.
Score: 0.032
-
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6.
Score: 0.032
-
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother. 2015 Sep; 21(9):663-7.
Score: 0.032
-
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
Score: 0.032
-
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93.
Score: 0.032
-
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904.
Score: 0.032
-
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther. 2015 Apr; 15(4):601-11.
Score: 0.032
-
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015 May; 39(5):520-4.
Score: 0.032
-
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015 Mar; 2(3):e118-28.
Score: 0.032
-
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
Score: 0.032
-
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
Score: 0.032
-
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.
Score: 0.032
-
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61.
Score: 0.032
-
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
Score: 0.031
-
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar 01; 21(5):985-94.
Score: 0.031
-
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7.
Score: 0.031
-
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
Score: 0.031
-
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
Score: 0.031
-
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.
Score: 0.031
-
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65.
Score: 0.031
-
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.
Score: 0.030
-
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9.
Score: 0.030
-
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
Score: 0.030
-
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.
Score: 0.030
-
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16.
Score: 0.030
-
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
Score: 0.030
-
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):395-400.e1.
Score: 0.030
-
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8.
Score: 0.029
-
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61.
Score: 0.029
-
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
Score: 0.029
-
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5.
Score: 0.029
-
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80.
Score: 0.029
-
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9.
Score: 0.029
-
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.
Score: 0.029
-
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86.
Score: 0.029
-
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
Score: 0.029
-
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.
Score: 0.029
-
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4.
Score: 0.028
-
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8.
Score: 0.028
-
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.
Score: 0.028
-
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
Score: 0.028
-
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
Score: 0.028
-
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74.
Score: 0.028
-
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
Score: 0.028
-
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43.
Score: 0.027
-
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
Score: 0.027
-
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
Score: 0.027
-
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
Score: 0.026
-
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.
Score: 0.026
-
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.
Score: 0.026
-
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35.
Score: 0.026
-
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70.
Score: 0.026
-
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8.
Score: 0.026
-
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9.
Score: 0.025
-
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 Dec 01; 118(23):6030-6.
Score: 0.025
-
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3.
Score: 0.025
-
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8.
Score: 0.025
-
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20; 29(18):2521-7.
Score: 0.024
-
Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9.
Score: 0.024
-
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26; 117(21):5600-6.
Score: 0.024
-
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011 Jan 15; 117(2):327-35.
Score: 0.023
-
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood. 2010 Jul 01; 115(26):5428-9.
Score: 0.023
-
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10.
Score: 0.023
-
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8.
Score: 0.022
-
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009 Aug 01; 27(22):3642-9.
Score: 0.021
-
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63.
Score: 0.021
-
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5.
Score: 0.021
-
Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90.
Score: 0.021
-
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb 26; 113(9):1892-8.
Score: 0.021
-
Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009 Apr; 33(4):565-6.
Score: 0.020
-
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
Score: 0.019
-
Chronic myeloid leukemia--some topical issues. Leukemia. 2007 Jul; 21(7):1347-52.
Score: 0.019
-
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9.
Score: 0.018
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
Score: 0.018
-
Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol. 2005 Dec; 84 Suppl 1:18-24.
Score: 0.017
-
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
Score: 0.016
-
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7.
Score: 0.016